A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease
Study sponsor: Enanta Pharmaceuticals, Inc · ENTA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2029-07Estimated
Enrollment · participants860Estimated
Source updated2026-11-02Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.